Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of AR-13324 in patients with elevated IOP
NCT01528787Phase 2Completed
- Sponsor
- Aerie Pharmaceuticals
- Start
- Mar 2012
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of netarsudil in open-angle glaucoma (OAG), ocular hypertension, sponsored by Aerie Pharmaceuticals. Started Mar 2012; status: completed.
02
Drugs
netarsudil
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT01528787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01528787.